Assignee
ACTUATE THERAPEUTICS INC
US·7 granted patents·6 pending applications·12 citations·filing 2018–2024
Top patents by PatentIndex Score
13 records- 0191US11980607B2Methods of treating malignant lymphoproliferative disordersACTUATE THERAPEUTICS INC·Filed 2022·Granted May 14, 2024·1 cites·17 claims
- 0290US11407759B2Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dioneACTUATE THERAPEUTICS INC·Filed 2018·Granted Aug 9, 2022·4 cites·18 claims
- 0386US11136334B2Solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dioneACTUATE THERAPEUTICS INC·Filed 2018·Granted Oct 5, 2021·5 cites·17 claims
- 0481US11510904B2Methods of treating malignant lymphoproliferative disordersACTUATE THERAPEUTICS INC·Filed 2019·Granted Nov 29, 2022·2 cites·24 claims
- 0579US2024366563A1Methods of treating malignant lymphoproliferative disordersACTUATE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0677US12116374B2Solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dioneACTUATE THERAPEUTICS INC·Filed 2022·Granted Oct 15, 2024·0 cites·16 claims
- 0777US2025115616A1Solid Forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dioneACTUATE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0875US2025115615A1Solid Forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dioneACTUATE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0973US12145943B2Solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dioneACTUATE THERAPEUTICS INC·Filed 2021·Granted Nov 19, 2024·0 cites·5 claims
- 1064US2025325517A1Oral dosage forms of elraglusibACTUATE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1153US2023062278A1Compounds for the treatment of myelofibrosisACTUATE THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1245US12083098B2Treatment of idiopathic pulmonary fibrosis with glycogen synthase kinase 3 form β inhibitorsACTUATE THERAPEUTICS INC·Filed 2019·Granted Sep 10, 2024·0 cites·8 claims
- 1334US2022034766A1Immunohistochemical staining for gsk-3ACTUATE THERAPEUTICS INC·Filed 2019·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →